How should BPC-157 be stored and reconstituted?

Lyophilised BPC-157 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What is the evidence base for BPC-157?

BPC-157's evidence base sits at preclinical + limited human. The references on this page summarise 3 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What should I look for in BPC-157 sourcing and quality?

Acceptable BPC-157 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1419.5 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Should I cycle BPC-157?

Standard cycle for BPC-157 is 8–12 weeks of 1-2x daily 250-500 mcg dosing via subq/oral, followed by a 4 week complete off-period. The off-period is calibrated to BPC-157's ~4 hr (oral) half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How long until I see results from BPC-157?

Acute effects from BPC-157 appear within the first week for downstream physiological adaptation. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ BPC-157

BPC-157

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: BPC-157 is evaluated by women's-health clinicians on multiple axes. Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair Modulates the gut-brain axis via vagal afferents to influence central serotonin and dopamine signalling. Reduces neuroinflammatory cytokines.. The compound's stable gastric pentadecapeptide pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

Mood (Cycle-Related)SleepCognitive (Cycle/Menopause)Libido (Female)Skin Health

Key Takeaways

Female-physiology lens: BPC-157 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 250-500 mcg 1-2x daily via subq/oral; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Modulates the gut-brain axis via vagal afferents to influence central serotonin and dopamine signalling. Reduces neuroinflammatory cytokines. Female-physiology implications operate across three life-stage contexts: pre-menopausal cyclical users, the perimenopausal transition, and post-menopausal users on or off HRT. BPC-157's response varies meaningfully across these contexts, as the subsections on cyclical context, perimenopause integration, fertility, and bone-and-cardiovascular signalling describe.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and BPC-157's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. BPC-157's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Fertility and reproductive considerations

BPC-157's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Perimenopause

Perimenopause is one of the dimensions on which women track BPC-157 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Vaginal Health

In the perimenopausal window, BPC-157 for vaginal health produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Endometriosis Support

For endometriosis support in female users, BPC-157 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Libido (Female)

Libido (Female) is one of the dimensions on which women track BPC-157 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	250-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	150-500 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	250-500 mcg	1-2x daily
Maintenance phase	SubQ	175-500 mcg	Ongoing with periodic pauses

Dose timing for BPC-157 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

BPC-157 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

BPC-157 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with BPC-157's mechanism in female physiology protocols.
BPC-157 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with BPC-157's mechanism in female physiology protocols.
BPC-157 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with BPC-157's mechanism in female physiology protocols.
BPC-157 + Epithalon: Identified by Khavinson in St. Pairs naturally with BPC-157's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Banned (2022→) FDA: Unapproved (Research Only) Research: Preclinical + Limited Human

Generally well tolerated in animal models. No large-scale human RCTs. Avoid in active cancer due to angiogenic activity.

Lens-specific safety considerations for female physiology use of BPC-157: Generally well tolerated in animal models. No large-scale human RCTs. Avoid in active cancer due to angiogenic activity. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Sikirić et al. — Pentadecapeptide BPC 157 and its effects on cytoprotection and tissue repair

PMID 10404425

Supporting

BPC 157 — angiogenic activity, VEGFR2 upregulation, and tissue protection

PMID 21030672

BPC-157 vs Related Peptides

Compound	Profile	Onset	Best For
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Will BPC-157 affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. BPC-157's specific interaction follows its mechanism.

How will BPC-157 interact with my cycle?

For pre-menopausal users, response to BPC-157 often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Does BPC-157 affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where BPC-157 specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

Can I use BPC-157 during pregnancy or while trying to conceive?

Most peptide therapeutics, including BPC-157, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

What is the mechanism of action of BPC-157?

Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Modulates the gut-brain axis via vagal afferents to influence central serotonin and dopamine signalling. Reduces neuroinflammatory cytokines. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the standard dosing protocol for BPC-157?

Conventional BPC-157 dosing is 250-500 mcg 1-2x daily via subq/oral. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a BPC-157 Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified BPC-157 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 1419.5 Da
Sequence length: 15 aa
Half-life: ~4 hr (oral)
WADA: Banned (2022→)
FDA: Unapproved (Research Only)
Research: Preclinical + Limited Human

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for BPC-157

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised